Satellite

Satellite

TMAO Association with Cardiometabolic Outcomes (breakfast provided)

Chair(s)

• 

  Andrew Shao, PhD

  Interim Senior Vice President
  Council for Responsible Nutrition

Co-Chair(s)

• AB

  Aouatef Bellamine, PhD

  Senior Scientific Manager
  Lonza Inc.

Speaker(s)

• CP

  Christopher Papandreou, PhD

  Senior Investigator
  Institut d'Investigació Sanitària Pere Virgili (IISPV)
• JC

  John Cashman, PhD

  President and Founder
  Human Biomolecular Research Institute (HBRI)

In 2011, Wang and colleagues published their initial findings linking high plasma trimethylamine-N-oxide (TMAO) with cardiovascular disease (CVD). Since then, TMAO's role in the etiology of cardiometabolic diseases remains a matter of controversy within the scientific community. In the PREDIMED trial, an inverse association between plasma TMAO levels with incident T2D was recently reported. In this symposium, Dr. Christopher Papandreou will present findings in relation to TMAO and cardiometabolic traits. TMAO production involves flavin-containing monoxygenases (FMO), a family of enzymes located in the liver and known to be modulated by different factors. Dr. Cashman will provide information on the FMO gene regulation and how this connects to cardiometabolic outcomes.

Learning Objectives:

• Elevated levels of TMAO are a marker for CVD, not the cause
• High TMAO levels shown to have protective benefits against T2D incidence
• Variability in the TMAO production is the result of variability in the microbiome and FMO gene regulation

Presentations:

• 7:00 AM - 8:45 AM

  Trimethylamine-N-oxide and Cardiometabolic Health
  John Cashman, PhD – Human Biomolecular Research Institute (HBRI)
• 7:00 AM - 8:45 AM

  Trimethylamine-N-oxide Association with Cardiometabolic Outcomes
  Christopher Papandreou, PhD – Institut d'Investigació Sanitària Pere Virgili (IISPV)